MVA E2

AXP000191.1 · Cancer vaccine

Platform
MVA
Originator
Instituto Mexicano del Seguro Social / Virolab
Sponsor
Virolab

Names

NameTypeSource
MVA E2preferred name, codecurator, paper
MVA E2 therapeutic vaccinesynonympaper

Virus

Role
Vaccine vector
Family
Poxviridae
Virus
vaccinia virus (NCBI Taxonomy 10245)
Strain
MVA
Replication
non replicating
Modifications
bovine papillomavirus E2 gene inserted into MVA
Transgenes
bovine papillomavirus E2
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (0)

No trial in the latest ClinicalTrials.gov snapshot names this program.

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 30605254MVA E2 therapeutic vaccine for marked reduction in likelihood of recurrence of respiratory papillomatosis.Head & neck2019name in title: MVA E2 therapeutic vaccine
PMID 25275724Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine.Human gene therapy2014name in title: MVA E2 therapeutic vaccine
PMID 17263589MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2007name in title: MVA E2
PMID 16456551Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine.Cancer gene therapy2006name in title: MVA E2
PMID 15144573Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus.Human gene therapy2004name in title: MVA E2
PMID 12067445Clinical protocol. A phase II study: efficacy of the gene therapy of the MVA E2 recombinant virus in the treatment of precancerous lesions (NIC I and NIC II) associated with infection of oncogenic human papillomavirus.Human gene therapy2002name in title: MVA E2

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41294662Advances in Therapeutic Vaccines Against HPV: A Review of Human Clinical Trials.Current oncology (Toronto, Ont.)2025name in abstract: MVA E2
PMID 35880341[Clinical research progress and implications of therapeutic vaccines for cervical cancer and precancerous lesions: a qualitative systematic review].Zhonghua zhong liu za zhi [Chinese journal of oncology]2022name in abstract: MVA E2
PMID 32390320Advances in therapeutic vaccines for treating human papillomavirus-related cervical intraepithelial neoplasia.The journal of obstetrics and gynaecology research2020name in abstract: MVA E2
PMID 19225922Medical treatment of cervical intraepithelial neoplasia II, III: an update review.International journal of clinical oncology2009name in abstract: MVA E2
PMID 10738224Human tumor growth is inhibited by a vaccinia virus carrying the E2 gene of bovine papillomavirus.Cancer2000name in abstract: MVA E2
PMID 10999461A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibody-dependent cytotoxicity.Cancer immunology, immunotherapy : CII2000name in abstract: MVA E2

Notes

MVA encoding the bovine papillomavirus E2 protein, injected locally into HPV-associated intraepithelial lesions (intrauterine in women, intraurethral in men, at the lesion base for vulvar/anal lesions). A phase 3 study of 1,356 patients in Mexico and Venezuela (2007-2012) reported 89.4% complete lesion elimination in women; the trial was largely uncontrolled and the paper's efficacy figures are internally inconsistent. Route recorded as topical/intralesional is not in the registry's route vocabulary, so route is left empty and described here.

How to cite

MVA E2 (AXP000191.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000191.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.